medigraphic.com
Colegio de Medicina Interna de México.

2018, Número 3

<< Anterior Siguiente >>

Med Int Mex 2018; 34 (3)


Síndrome hemolítico urémico atípico: papel del perfil genético

Roldán-Tabares MD, Ruiz-Mejía C

Idioma: Español
Referencias bibliográficas: 46
Paginas: 394-402
Archivo PDF: 397.68 Kb.


RESUMEN

El síndrome hemolítico urémico es una microangiopatía trombótica caracterizada por anemia hemolítica microangiopática, trombocitopenia y daño renal agudo. El síndrome hemolítico urémico típico (el más común) es ocasionado por bacterias productoras de la toxina Shiga, típicamente por cepas de Escherichia coli. El término síndrome hemolítico urémico atípico se usa para referirse a los pacientes que padecen este cuadro por causas diferentes. Las manifestaciones clínicas y paraclínicas no son suficientes para diferenciar el síndrome hemolítico urémico atípico de otras microangiopatías trombóticas, por lo que la determinación de la actividad de ADAMTS13 y la prueba de la toxina Shiga resultan esenciales para establecer el diagnóstico preciso. Aunque en la actualidad el diagnóstico definitivo requiere confirmación genética, las pruebas genéticas son costosas y poco útiles para el diagnóstico inicial; sin embargo, más que importancia diagnóstica, tiene gran valor pronóstico, permite prescribir el tratamiento adecuado disminuyendo significativamente la morbilidad y mortalidad atribuibles a esta enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gavriilaki E, Yuan X, Ye Z, Ambinder A, Shanbhag S, Streiff M, et al. Modified Ham test for atypical hemolytic uremic syndrome. Blood 2015;125(23):3637-46. DOI:10.1182/ blood-2015-02-629683

  2. Nester C, Barbour T, de Cordoba S, Dragon-Durey M, Fremeaux-Bacchi V, Goodship T, et al. Atypical aHUS: state of the art. Mol Immunol 2015;67(1):31-42. DOI:10.1016/j. molimm.2015.03.246

  3. Nozal P, Bernabéu-Herrero ME, Uzonyi B, Szilágyi Á, Hyvärinen S, Prohászka Z, et al. Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome. Mol Immunol 2016;70:47-55.DOI: 10.1016/j. molimm.2015.12.005

  4. Durkan A, Kim S, Craig J, Elliott E. The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study. Arch Dis Child 2016;101(4):387-91. DOI: 10.1136/archdischild-2015-309471.

  5. Frimat M, Tabarin F, Dimitrov JD, Poitou C, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 2013;122(2):282-292. DOI: 10.1182/ blood-2013-03-489245

  6. Jamme M, Raimbourg Q, Chauveau D, Seguin A, Presne C, Perez P, et al. Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. PLoS One 2017;12(5):e0177894. DOI: 10.1371/journal. pone.0177894

  7. Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013;45(5):531-36. DOI: 10.1038/ng.2590

  8. Bu F, Maga T, Meyer N, Wang K, Thomas C, Nester C, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014;25(1):55-64. DOI: 10.1681/ASN.2013050453

  9. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey M, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013;8(4):554-62. DOI: 10.2215/CJN.04760512

  10. Afshar V. Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program 2016(1):217-25. DOI: 10.1182/asheducation-2016.1.217

  11. Pelicano M, Rodríguez S, Campistol J. Síndrome hemolítico urémico atípico. Med Clin 2014;145(10):438-45. DOI:10.1016/j.medcli.2014.08.006

  12. Greenbaum L. Atypical hemolytic uremic syndrome. Advances in pediatrics. 2014;6(1):335-56. DOI: 10.1016 / j.yapd.2014.04.001

  13. Mahmood U, Isbel N, Mollee P, Mallett A, Govindarajulu S, Francis R, et al. Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome. APSN 2017;22(1):15-17. DOI: 10.1111/nep.12934

  14. Fakhouri F, Roumenina L, Provot F, Sallée M, Caillard S, Couzi L, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. JASN 2010;21(1):859-67. DOI:10.1681/ASN.2009070706

  15. Gately R, San A, Kurtkoti J, Parnham A. Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab. APSN 2017;22(1):32-5. DOI: 10.1111/nep.12938

  16. Song D, Yu X, Wang F, Xu B, He Y, Chen Q, et al. Overactivation of complement alternative pathway in postpartum atypical hemolytic uremic syndrome patients with renal involvement. Am J Reprod Immunol 2015;74(4):345-56. DOI:10.1111/aji.12404

  17. Blasco M, Rodríguez S, Campistol J. Atypical hemolytic uraemic síndrome. Med Clin (Barc) 2015;145(10):438-45. DOI: 10.1016/j.medcli.2014.08.006

  18. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, et al. Thrombomodulin mutations in atypical hemolytic- uremic syndrome. N Engl J Med 2009;361(4):345- 57. DOI: 10.1056/NEJMoa0810739

  19. De Andrade LGM, Contti MM, Nga HS, Bravin AM, et al. Long-term outcomes of the atypical hemolytic uremic syndrome after kidney transplantation treated with eculizumab as first choice. PLoS One 2017;12(11):e0188155. DOI: 10.1371/journal.pone.0188155

  20. Coppo R, Bonaudo R, Peruzzi RL, Amore A, Brunati A, Romagnoli R, et al. Liver transplantation for aHUS: still needed in the eculizumab era? Pediatr Nephrol 2016 ;31(5):759- 768. DOI: 10.1007/s00467-015-3278-0

  21. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux- Bacchi V, Rodriguez de Cordoba S, et al. Combined com plement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013;24(3):475-86. DOI: 10.1681/ASN.2012090884

  22. Zuber J, Fakhouri F, Roumenina L, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8(11):643-57. DOI: 10.1038/nrneph.2012.214

  23. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5(10):1844-59. DOI:10.2215/CJN.02210310

  24. Ruebner RL, Kaplan BS, Copelovitch L. A time for reappraisal of “atypical” hemolytic uremic syndrome: should all patients be treated the same? Eur J Pediatr 2012;171(10):1519-25. DOI: 10.1007/s00431-012-1763-z

  25. Nayer A, Asif A. Atypical hemolytic-uremic syndrome: A clinical review. Am J Ther 2016;23(1):151-158. DOI:10.1097/ MJT.0b013e31829b59dc

  26. Campistol J, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, et al. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrologia 2015(35):421-47. DOI: 10.1016/j.nefro.2015.07.005

  27. Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 2014;29(10):1967-78. DOI: 10.1007/s00467-014-2817-4

  28. Zheng X, Gorovoy IR, Mao J, Jin J, Chen X, Cui QN. Recurrent ocular involvement in pediatric atypical hemolytic uremic syndrome. J Pediatr Ophthalmol Strabismus 2014;51:e62- 5. DOI: 10.3928/01913913-20140923-03.

  29. Magro CM, Momtahen S, Mulvey JJ, Yassin AH, Kaplan RB, Laurence JC. Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome. Am J Dermatopathol 2015;37(5):349-56. DOI: 10.1097/DAD.0000000000000234

  30. Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, et al; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. 2016;28:549-55. DOI: 10.1111/ped.13044

  31. Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis 2014;63(1):40-8. DOI: 10.1053/j.ajkd.2013.07.011

  32. Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP. Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission. Clin Exp Immunol 2015;181(2):306-13. DOI: 10.1111/cei.12426.

  33. Mannucci P. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: Much progress and many remaining issues. Haematologica 2007;92(7):878-80. DOI:10.3324/haematol.11196

  34. Alvarez-Larrán A, del Río-Garma J, Pujol M, de la Rubia J, Hernández-Jodra M, Borrell M, et al. Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment. Ann Hematol 2009;88(10): 973-8. DOI: 10.1007/s00277-009-0707-9

  35. Contreras E, de la Rubia J, Del Río-Garma J, Díaz-Ricart M, García-Gala JM, Lozano M. Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group. Med Clin (Barc) 2015; 144(7): 331.e1-331. e13. DOI: 10.1016/j.medcli.2014.09.013

  36. Cataland SR, Wu HM. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 2014;123(16):2478-84. DOI: 10.1182/blood-2013-11-516237

  37. Phillips EH, Westwood JP, Brocklebank V, Wong EK, Tellez JO, Marchbank KJ, et al. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost 2016;14(1):175-185. DOI: 10.1111/jth.13189

  38. Williams LA, Marques MB; Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs). Am J Clin Pathol 2016;145(2):158-165. DOI: 10.1093/ajcp/aqv086

  39. Bello DC. Síndrome hemolítico urémico. CCAP 2016;14(4):57- 68.

  40. Canpolat N. Hemolytic uremic syndrome. Turk Pediatri Ars 2015;50(2):73-82. DOI: 10.5152 / tpa.2015.2297

  41. Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013;13(3):663-675. DOI: 10.1111/ajt.12077

  42. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368(23):2169-2181. DOI: 10.1056/NEJMoa1208981

  43. Bhatia D, Khandelwal P, Sinha A, Hari P, Cheong HI, Bagga A. Incomplete penetrance of CD46 mutation causing familial atypical hemolytic uremic syndrome. Pediatr Nephrol 2015;30(12):2215-2220. DOI: 10.1007/s00467-015-3189-0

  44. Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey MA, Bordereau P, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 2012;119(18):4182-91. DOI: 10.1182/blood-2011-10-383281

  45. Funato M, Uemura O, Ushijima K, Ohnishi H, Orii K, Kato Z, et al. A complement factor B mutation in a large kindred with atypical hemolytic uremic syndrome. J Clin Immunol 2014;34(6):691-695. DOI: 10.1007/s10875-014-0058-8

  46. Azukaitis K, Simkova E, Majid MA, Galiano M, Benz K, Amann K, et al. The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase ε. J Am Soc Nephrol 2017;28(10):3066-3075. DOI: 10.1681/ ASN.2017010031




2020     |     www.medigraphic.com